When was Broken String Biosciences founded?

Broken String Biosciences was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Broken String Biosciences located?

Broken String Biosciences is headquartered in Cambridge, United Kingdom.

Who is the current CEO of Broken String Biosciences?

Felix Dobbs of Broken String Biosciences. They have also founded 1 company.

Which legal entities is Broken String Biosciences associated with?

Broken String Biosciences is associated with Broken String Biosciences Ltd.

How many employees does Broken String Biosciences have?

As of Jun 30, 2026, the latest employee count at Broken String Biosciences is 37.

Is Broken String Biosciences a funded company?

Broken String Biosciences is a funded company, having raised a total of $15M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 08, 2021.

When was the latest funding round of Broken String Biosciences?

Broken String Biosciences' latest funding was a $***** Series A round on Sep 18, 2023, with participation from 5 investors.

Where does Broken String Biosciences rank among its competitors?

Broken String Biosciences ranks 11th amongst 512 active competitors, of which 83 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was SeqOne, which secured $22.7M in May, 2025.

Who are the top competitors of Broken String Biosciences?

Broken String Biosciences' top competitors include DNAnexus, Twin Strand Bio and Deep Genomics. Among them, SeqOne secured the most recent funding round in May, 2025.

Broken String Biosciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Broken String Biosciences is a series A company based in Cambridge (United Kingdom), founded in 2020 by Felix Dobbs, Patrick van Eijk and Simon Reed. It operates as a Developer of biopharmaceutical products & cell therapies by using genome sequencing data. Broken String Biosciences has raised $15M in funding from investors like Illumina, Dieter von Holtzbrinck Ventures and Illumina Ventures. The company has 512 active competitors, including 83 funded and 41 that have exited. Its top competitors include companies like DNAnexus, Twin Strand Bio and Deep Genomics.

Company Details

Developer of biopharmaceutical products & cell therapies by using genome sequencing data. It has developed sequencing tools that help in the development of medicines, including cell and gene therapies for the treatment of cancer, immunological health & other diseases. It develops INDUCE-seq technology for measuring DNA breaks throughout the genome & also determines the mechanism of DSB repair that facilitates the development of therapeutic genome editing.

Website: www.brokenstringbio.com/
Social

Key Metrics

Founded Year

2020

Location

Cambridge, United Kingdom

Stage

Series A

Total Funding

$15M in 3 rounds

Latest Funding Round

Series A, Sep 18, 2023, $*****

Investors

Illumina & 15 more

Ranked

11^th among 512 active competitors

Employee Count

37 as on Jun 30, 2026

Similar Companies

DNAnexus & 682 more

View Broken String Biosciences' full profile

Broken String Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Broken String Biosciences Ltd CIN: 12420619 , United Kingdom, Active	Jan 22, 2020	-	-

Broken String Biosciences has raised a total funding of $15M over 3 rounds. Its first funding round was on Feb 08, 2021. Its latest funding round was a Series A round on Sep 18, 2023 for $*****. 5 investors participated in its latest round. Broken String Biosciences has 13 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of Broken String Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 18, 2023	1100085	Series A	6576173	5378830	5753417	3439713
Jan 21, 2022	5327686	Seed	5305503	4416168	7153561	7485415
Feb 08, 2021	9873610	Seed	8743805	4798648	Illumina	1751196

Access funding benchmarks and valuations. Sign up today!

View details of Broken String Biosciences's funding rounds and investors

The founders of Broken String Biosciences are Felix Dobbs, Patrick van Eijk and Simon Reed. Felix Dobbs is the CEO of Broken String Biosciences.

Here are the details of Broken String Biosciences' key team members:

Felix Dobbs: Co-Founder & CEO of Broken String Biosciences.
Contact Info: 1 email address
Patrick van Eijk: Co-Founder & CTO of Broken String Biosciences.
Simon Reed: Co-Founder & CSO of Broken String Biosciences.
Contact Info: 1 email address

View details of Broken String Biosciences's Founder profiles and Board Members

Broken String Biosciences' employee count trend

Broken String Biosciences has 37 employees as of Jun 26. Here is Broken String Biosciences's employee count trend over the years:

Employee count trend for Broken String Biosciences

Uncover Broken String Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Broken String Biosciences include DNAnexus, Twin Strand Bio and Deep Genomics. Here is the list of Top 10 competitors of Broken String Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	71/100
2nd	Twin Strand Bio 2015, Seattle (United States), Series B	Developer of DNA sequencing technology to identify genomic mutations	$84M	S32, Madrona & 9 others	65/100
3rd	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	True Ventures, Future Ventures & 16 others	63/100
4th	Hexagon Bio 2017, Menlo Park (United States), Series B	Provider of bioinformatics tools for the analysis of microbial genomic sequencing data	$206M	Nextech Invest, The Column Group & 10 others	63/100
5th	Genomenon 2014, Ann Arbor (United States), Series B	Provider of software, data, and services for genomic information analysis	$36.8M	Michigan Rise, Spring Mountain Capital & 19 others	58/100
6th	BC Platforms 1997, Zurich (Switzerland), Series D	Provider of a platforms for genomic data analysis and management	$47.1M	Debiopharm, Jolt Capital & 6 others	58/100
7th	SeqOne 2017, Montpellier (France), Series A	Provider of bioinformatics tools for the analysis of genome sequencing data	$48.8M	Elaia, Supernova Invest & 7 others	57/100
8th	Molecular Health 2004, Heidelberg (Germany), Late Stage	Genomic software solutions for healthcare providers	$26.9M	Dievini, The University of Texas at Austin ... & 1 others	56/100
9th	Fabric Genomics 2009, Oakland (United States), Acquired	AI-based disease diagnosis and genomic analysis tool for providers	$32.8M	Artis Ventures, UPMC & 12 others	55/100
10th	Linus Biotechnology 2020, New York City (United States), Series A	Developer of diagnostic tests for central nervous system and gastrointestinal disorders	$47.6M	GreatPoint Ventures, Bow Capital & 3 others	55/100
11th	Broken String Biosciences 2020, Cambridge (United Kingdom), Series A	Developer of biopharmaceutical products & cell therapies by using genome sequencing data	$15M	Illumina, Tencent & 14 others	55/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Broken String Biosciences's competitors? Click here to see the top ones

Broken String Biosciences has made no investments or acquisitions yet.

Here is the latest report on Broken String Biosciences's geography:

Free

UK Tech Quarter Funding Report

Edition: Quarter 1, 2026 (47 Pages)

View all reports related to Broken String Biosciences

Media has covered Broken String Biosciences for a total of 2 events in the last 1 year, 1 of them has been about company updates and 1 about people movement.